Picard Medical, the parent company of SynCardia Systems, has announced the successful first in vivo implantations of the Emperor Total Artificial Heart (TAH), the company’s fully implantable next-generation system.
The results mark a significant step forward in the development of the Emperor platform, which is intended to succeed the clinically proven, FDA-approved SynCardia Total Artificial Heart.
The Emperor TAH was implanted in three pre-clinical models, each removed from bypass smoothly and without complications. During monitoring, the device demonstrated full and stable circulation, efficient energy use and reliable function.
Its performance closely replicated the behaviour of a natural heart, including stable blood flow, natural adjustment to changes in blood volume entering the device, and consistent output even as vascular resistance varied. These outcomes align with engineering targets set for the platform.
The company will continue pre-clinical testing as development progresses. The Emperor platform aims to widen access to artificial heart therapy by providing a fully implantable system with improved performance and usability.
The technology is being positioned as a potential future option for patients requiring an alternative to heart transplantation.
